Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q3 2025 (September 30)3holders −2
0new positions
2sold out
$2.58avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, down 2 from Q2 2025. 0 opened new positions and 2 sold out. The largest holders were Boothbay Fund Management, LLC ($60K), Susquehanna International Group, LLP ($225) and UBS Group AG ($22).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $232 |
All 13F filers, Q2 2025 → Q3 2025: 25,119 shares sold, net −25,119 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $60K |
| Susquehanna International Group, LLP | — | Reduce -5.1% | 10,176 | $225 |
| UBS Group AG | — | Reduce -32.0% | 1,279 | $22 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.